

barbiturate and non-benzodiazepine hypnotic compound and melatonin;

Group III: claim 46, drawn to a method of decreasing the dose of a non-barbiturate or non-benzodiazepine hypnotic compound through combination treatment with melatonin; and

Group IV: claim 47, drawn to a method of lessening the risk of the development of tolerance or dependence on a non-barbiturate or non-benzodiazepine hypnotic compound through combination treatment with melatonin.

Applicants hereby elect the claims of Group I, claims 29-37, for prosecution on the merits.

The examiner further has requested an election of species.
Applicants hereby elect zolpidem (N,N,6-trimethyl-2-(4-

Serial No. 10/510,625
Reply to Office action dated March 5, 2009
Page 3

methylphenyl)-imidazo(1,2-a)pyridine-3-acetamide) as the non-barbiturate and non-benzodiazepine compound.

<input checked="" type="checkbox"/> Customer Number or Bar Code Label 6449					
Name	Barbara G. Ernst, Reg. No. 30,377				
Signature	/ Barbara G. Ernst /		Date	March 26, 2009	
Address	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031